Literature DB >> 1427414

Low-dose aspirin in primigravidae with positive roll-over test.

H Schröcksnadel1, B Sitte, A Alge, G Steckel-Berger, P Schwegel, E Pastner, G Daxenbichler, H Hansen, O Dapunt.   

Abstract

In a prospective, randomized, double-blind study for the prevention of pregnancy-induced hypertension and preeclampsia, 41 primigravidae with positive roll-over test (28th-32nd week of pregnancy) received 80 mg aspirin/day or placebo until the end of the 37th week. In the patients treated with acetylsalicylic acid (n = 22), 3 cases of proteinuria occurred, but no hypertensive pregnancy complication. In the placebo group (n = 19), 10 patients developed pregnancy-induced hypertension (6 of them preeclampsia). Group-specific differences concerning the occurrence of hypertension were statistically highly significant (p = 0.0004). No relevant differences were observed with regard to pregnancy duration, birth weight and umbilical artery pH value. The placebo group included 1 intrauterine death. No increased tendency to maternal or fetal bleeding was noticed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1427414     DOI: 10.1159/000292748

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  3 in total

1.  Antiplatelet agents for preventing pre-eclampsia and its complications.

Authors:  Lelia Duley; Shireen Meher; Kylie E Hunter; Anna Lene Seidler; Lisa M Askie
Journal:  Cochrane Database Syst Rev       Date:  2019-10-30

Review 2.  Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis.

Authors:  Ting-ting Xu; Fan Zhou; Chun-yan Deng; Gui-qiong Huang; Jin-ke Li; Xiao-dong Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-04-02       Impact factor: 3.738

Review 3.  Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths.

Authors:  Mehnaz Jabeen; Mohammad Yawar Yakoob; Aamer Imdad; Zulfiqar A Bhutta
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.